Clinical Trials Browser

Lymphoma, Extranodal NK-T-Cell × Gemcitabine × Clear all

NCT05700448 2026-02-05

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

Phase 3 Not yet recruiting

Lymphoma, Extranodal NK-T-Cell

NCT05774028 2023-03-17

Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma

Phase 2 Unknown

Lymphoma, Extranodal NK-T-Cell

NCT03052933 2022-06-10

Copanlisib and Gemcitabine in Relapsed/Refractory PTCL

Phase 1/2 Completed

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT05254899 2022-02-24

Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL

Phase 2 Unknown

Lymphoma, Extranodal NK-T-Cell

NCT02733458 2021-09-14

GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell Lymphoma

Phase NA Completed

Lymphoma, Extranodal NK-T-Cell

NCT04917250 2021-06-08

GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Phase 2 Unknown

Lymphoma, Extranodal NK-T-Cell

NCT02085655 2021-03-15

PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma

Phase 3 Unknown

Lymphoma, Extranodal NK-T-Cell

NCT04230330 2020-11-05

Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma

Phase 1 Withdrawn

Lymphoma, Extranodal NK-T-Cell

NCT04405375 2020-05-28

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

Phase 2 Unknown

LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

NCT02359162 2018-05-09

Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage

Phase 3 Terminated

Lymphoma, Extranodal NK-T-Cell

NCT02533323 2018-05-09

P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens

Phase 2 Terminated

Lymphoma, Extranodal NK-T-Cell

NCT00072514 2017-06-29

Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies

Phase 2 Completed

55 enrolled 6 charts

DermatologicLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT01991158 2016-06-14

GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma

Phase 2 Unknown

Lymphoma, Extranodal NK-T-Cell

NCT02080234 2016-04-20

Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL

Phase 2 Unknown

Lymphoma, Extranodal NK-T-Cell

NCT01921790 2013-08-22

Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma

Phase 2 Unknown

Lymphoma, Extranodal NK-T-Cell